Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction.

ABSTRACT:

Importance

Accurate risk prediction of morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF) may help clinicians risk stratify and inform care decisions.

Objective

To develop and validate a novel prediction model for clinical outcomes in patients with HFpEF using routinely collected variables and to compare it with a biomarker-driven approach.

Design, setting, and participants

Data were used from the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial to derive the prediction model, and data from the Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction (PARAGON-HF) and the Irbesartan in Heart Failure With Preserved Ejec

SUBMITTER: McDowell K 

PROVIDER: S-EPMC10974691 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature